Novartis has reported positive clinical trial data from three studies of QVA149, its innovative new therapy for chronic obstructive pulmonary disease (COPD).
Results have emerged from Shine, Bright and Enlighten, the first three trials in the Ignite study programme, which aims to provide detailed data on the safety and efficacy of the dual-mode bronchodilator.
The drug was able to meet its primary endpoints in all three of the studies after demonstrating superior performance to placebo and an alternative therapy option.
A further seven trials will be completed as part of the Ignite programme, with the data set to support regulatory filings for the compound later this year.
Tim Wright, head of development at Novartis Pharmaceuticals, said: "Meeting the primary endpoints ... signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio."
Last month, the company received a provisional recommendation from the National Institute for Health and Clinical Excellence for its multiple sclerosis therapy Gilenya.